Development of a highly thermostable, adjuvanted human papillomavirus vaccine.
Eur J Pharm Biopharm
; 94: 220-8, 2015 Aug.
Article
em En
| MEDLINE
| ID: mdl-25998700
ABSTRACT
A major impediment to economical, worldwide vaccine distribution is the requirement for a "cold chain" to preserve antigenicity. We addressed this problem using a model human papillomavirus (HPV) vaccine stabilized by immobilizing HPV16 L1 capsomeres, i.e., pentameric subunits of the virus capsid, within organic glasses formed by lyophilization. Lyophilized glass and liquid vaccine formulations were incubated at 50°C for 12weeks, and then analyzed for retention of capsomere conformational integrity and the ability to elicit neutralizing antibody responses after immunization of BALB/c mice. Capsomeres in glassy-state vaccines retained tertiary and quaternary structure, and critical conformational epitopes. Moreover, glassy formulations adjuvanted with aluminum hydroxide or aluminum hydroxide and glycopyranoside lipid A were not only as immunogenic as the commercially available HPV vaccine Cervarix®, but also retained complete neutralizing immunogenicity after high-temperature storage. The thermal stability of such adjuvanted vaccine powder preparations may thus eliminate the need for the cold chain.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Proteínas Oncogênicas Virais
/
Adjuvantes Imunológicos
/
Proteínas do Capsídeo
/
Vacinas contra Papillomavirus
Limite:
Animals
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article